PTO/SB/26 (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING	Docket Number (Optional)	
REJECTION OVER A "PRIOR" PATENT	597932000200	
In re Application of: Victor V. GOGOLAK		
Application No.: 09/681,586		
Filed: May 2, 2001		
For: METHOD FOR GRAPHICALLY DEPICTING DRUG ADVERSE EFFECT RISKS		
The owner*, Victor V. Gogolak , of		
instant application hereby disclaims, except as provided below, the terminal part of the statutory instant application which would extend beyond the expiration date of the full statutory term of prior		
as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened		
by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instart only for and during such period that it and the prior patent are commonly owned. This agrees on the instant application and is binding upon the grantee, its successors or assigns.	near runs with any patent granted	
In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent		
later: expires for failure to pay a maintenance fee;		
is held unenforceable; is found invalid by a court of competent jurisdiction;		
is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate;		
is reissued; or	anad by any terminal disclaimer	
is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. Check either box 1 or 2 below, if appropriate.		
1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.		
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information		
and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.		
2. X The undersigned is an attorney or agent of record. Reg. No. 36,119		
	·····	
Adam Keser, 54,217	July 27, 2010	
Signature	Date	
For Peter J. Davis		
Typed or printed name		
·	(703) 760-7748	
V Tausiant disclaiment for under 27 CED 4 20/d) is included	Telephone Number	
X Terminal disclaimer fee under 37 CFR 1.20(d) is included.	information about 4 not	
WARNING: Information on this form may become public. Credit card be included on this form. Provide credit card information and authori	zation on PTO-2038.	
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.		

PTO/SB/26 (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING	Docket Number (Optional)	
REJECTION OVER A "PRIOR" PATENT	597932000200	
In re Application of: Victor V. GOGOLAK		
Application No.: 09/681,586 Filed: May 2, 2001		
Flied: May 2, 2001	·	
For: METHOD FOR GRAPHICALLY DEPICTING DRUG ADVERSE EFFECT RISKS		
The owner*, Victor V. Gogolak , of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of prior patent No. 7,461,006 as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant		
application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent		
later: expires for failure to pay a maintenance fee;		
is held unenforceable; is found invalid by a court of competent jurisdiction;		
is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;		
has all claims canceled by a reexamination certificate; is reissued; or		
is in any manner terminated prior to the expiration of its full statutory term as presently short	ened by any terminal disclaimer.	
Check either box 1 or 2 below, if appropriate.		
1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.		
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information		
and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.		
00.440		
2. X The undersigned is an attorney or agent of record. Reg. No. 36,119		
Adam Keser, 54,217	Luby 27, 2010	
Adam Keser, 54,217 Signature	July 27, 2010 Date	
- Cignatal C		
For Peter J. Davis		
Typed or printed name	(700) 700 7740	
	(703) 760-7748 Telephone Number	
	relephone Number	
Terminal disclaimer fee under 37 CFR 1.20(d) is included.		
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.		
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.		
	•	
1		